T-1101 Accepted for Online Publication at the 2025 ASCO Annual Meeting, Showcasing Innovative Mechanism and Clinical Potential
Taivex announced that the latest clinical trial data for its novel anticancer drug candidate T-1101 has been accepted for online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. As one of the world’s most prestigious oncology conferences, ASCO received over 7,500 abstract submissions this year. The selection of T-1101 underscores the …